Literature DB >> 17874969

Emerging drugs for epilepsy.

Patrick Kwan1, Martin J Brodie.   

Abstract

Epilepsy affects < or = 1% of the world's population. Antiepileptic drugs (AEDs) are the mainstay of treatment, although more than a third of patients are not rendered seizure free with existing medications. Uncontrolled epilepsy is associated with increased mortality and physical injuries, and a range of psychosocial morbidities, posing a substantial economic burden on individuals and society. Limitations of the present AEDs include suboptimal efficacy and their association with a host of adverse reactions. Continued efforts are being made in drug development to overcome these shortcomings employing a range of strategies, including modification of the structure of existing drugs, targeting novel molecular substrates and non-mechanism-based drug screening of compounds in traditional and newer animal models. This article reviews the need for new treatments and discusses some of the emerging compounds that have entered clinical development. The ultimate goal is to develop novel agents that can prevent the occurrence of seizures and the progression of epilepsy in at risk individuals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17874969     DOI: 10.1517/14728214.12.3.407

Source DB:  PubMed          Journal:  Expert Opin Emerg Drugs        ISSN: 1472-8214            Impact factor:   4.191


  9 in total

Review 1.  Pharmacological Management of the Genetic Generalised Epilepsies in Adolescents and Adults.

Authors:  Linda J Stephen; Martin J Brodie
Journal:  CNS Drugs       Date:  2020-02       Impact factor: 5.749

2.  General surgery among long-term residents with and without active epilepsy at the Kork Epilepsy Centre - a prospective comparative one-year survey.

Authors:  Bernhard J Steinhoff; Ralph Hartmann; Matthias Luy; Angelika Rombach; Gerhard Ziegler; Jürgen Schulte-Mönting; Frank G Gilliam
Journal:  Eur Neurol       Date:  2010-08-03       Impact factor: 1.710

3.  Cannabidivarin is anticonvulsant in mouse and rat.

Authors:  A J Hill; M S Mercier; T D M Hill; S E Glyn; N A Jones; Y Yamasaki; T Futamura; M Duncan; C G Stott; G J Stephens; C M Williams; B J Whalley
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

Review 4.  Pharmacotherapy of epilepsy: newly approved and developmental agents.

Authors:  Linda J Stephen; Martin J Brodie
Journal:  CNS Drugs       Date:  2011-02       Impact factor: 5.749

5.  Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo.

Authors:  Nicholas A Jones; Andrew J Hill; Imogen Smith; Sarah A Bevan; Claire M Williams; Benjamin J Whalley; Gary J Stephens
Journal:  J Pharmacol Exp Ther       Date:  2009-11-11       Impact factor: 4.030

6.  Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders.

Authors:  Giulia Curia; Giuseppe Biagini; Emilio Perucca; Massimo Avoli
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

7.  Experimental re-evaluation of flunarizine as add-on antiepileptic therapy.

Authors:  Anamika Thakur; A K Sahai; J S Thakur
Journal:  J Pharm Bioallied Sci       Date:  2011-04

Review 8.  Antiepileptic drugs in development pipeline: A recent update.

Authors:  Harjeet Kaur; Baldeep Kumar; Bikash Medhi
Journal:  eNeurologicalSci       Date:  2016-06-17

9.  Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression.

Authors:  Naoki Amada; Yuki Yamasaki; Claire M Williams; Benjamin J Whalley
Journal:  PeerJ       Date:  2013-11-21       Impact factor: 2.984

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.